S. Uggeri

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Gadducci, A. Lissoni, S. Cosio, 2024, The Lancet. Oncology.